Medically reviewed by Drugs.com. Last updated on Jul 9, 2019.
(pa PAV er een)
- Papaverine HCl
- Papaverine Hydrochloride
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Solution, Injection, as hydrochloride:
Generic: 30 mg/mL (2 mL, 10 mL [DSC])
Smooth muscle spasmolytic producing a generalized smooth muscle relaxation including: vasodilatation, gastrointestinal sphincter relaxation, bronchiolar muscle relaxation, and potentially a depressed myocardium (with large doses); muscle relaxation may occur due to inhibition or cyclic nucleotide phosphodiesterase, increasing cyclic AMP; muscle relaxation is unrelated to nerve innervation; papaverine increases cerebral blood flow in normal subjects; oxygen uptake is unaltered
Primarily urine (as metabolites)
Onset of Action
30 to 120 minutes
Use: Labeled Indications
Various vascular spasms associated with smooth muscle spasms as in myocardial infarction, angina, peripheral and pulmonary embolism, peripheral vascular disease; cerebral angiospastic states; visceral spasms (ureteral, biliary, and GI colic). Note: Labeled uses have fallen out of favor; safer and more effective alternatives are available.
Off Label Uses
Cerebral vasospasm after mechanical thrombectomy in acute ischemic stroke
Data from a limited number of patients studied suggest that intra-arterial papaverine may be beneficial for the treatment of cerebral vasospasm resulting from mechanical thrombectomy in acute ischemic stroke [Baltsavias 2015]. Additional data may be necessary to further define the role of papaverine in this condition.
Vasospasm during harvesting mammary arteries for CABG surgery
Data from a randomized controlled trial in patients undergoing CABG surgery and harvesting of the left internal mammary artery (LIMA) supports the use of intraluminal papaverine to prevent or treat spasm after LIMA dissection when delivered to the pedicle [Girard 2004]. Additional trials may be necessary to further define the role of papaverine to treat spasm of the internal mammary artery.
Complete AV block
Note: Labeled uses have fallen out of favor; safer and more effective alternatives are available. The manufacturer's labeling recommends the following dosing:
Arterial spasm: IM, IV: 30 to 120 mg; may repeat dose every 3 hours; if cardiac extrasystole occurs during use, may administer 2 doses 10 minutes apart
Cerebral vasospasm after mechanical thrombectomy in acute ischemic stroke (off-label use): Intra-arterial: 30 mg/minute; amount infused depends on response of the spastic vessel; dosage administered in clinical study ranged from 45 to 120 mg (Baltsavias 2015). Additional data may be necessary to further define the role of papaverine in this condition.
Vasospasm during harvesting mammary arteries for CABG surgery (off-label use): Intra-arterial: 10 mg (1 mg/mL in NS) injected throughout the vessel after it has been harvested; avoid vascular wall infiltration (Girard 2004). Note: Administration techniques may vary.
Refer to adult dosing.
Peripheral arterial catheter patency: Limited data available: Infants, Children, and Adolescents: Add 30 mg papaverine to an admixture of 250 mL NS or 1/2NS with heparin 1 unit/mL (Heulitt 1993; Kliegman 2007); infuse via peripheral arterial catheter; some centers report infusions at ≤1 mL/hour
Solutions should be clear to pale yellow. Precipitates with lactated Ringer's.
IV: Administer by slow push (over 1 to 2 minutes). Rapid IV administration may result in arrhythmias and fatal apnea.
May be administered intra-arterially for cerebral vasospasm after mechanical thrombectomy in acute ischemic stroke (off-label use) or vasospasm during harvesting mammary arteries for CABG surgery (off-label use) once the artery has been dissected (Baltsavias 2015; Girard 2004).
May be taken with food.
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light.
Levodopa-Containing Products: Papaverine may enhance the hypotensive effect of Levodopa-Containing Products. Papaverine may diminish the therapeutic effect of Levodopa-Containing Products. Monitor therapy
Frequency not defined.
Cardiovascular: Cardiac arrhythmia (with rapid IV use), flushing, hypertension (mild), tachycardia
Central nervous system: Headache, malaise, sedation, vertigo
Dermatologic: Diaphoresis, skin rash
Gastrointestinal: Abdominal distress, anorexia, constipation, diarrhea, nausea
Hepatic: Hepatic cirrhosis
Hypersensitivity: Hypersensitivity reaction (hepatic)
Respiratory: Apnea (with rapid IV use)
<1%, postmarketing, and/or case reports: Hepatitis
Concerns related to adverse effects:
• Arrhythmias: May (in large doses or with rapid infusion) depress AV and intraventricular cardiac conduction leading to serious arrhythmias (eg, premature beats, paroxysmal tachycardia).
• Hepatitis: May cause hepatic hypersensitivity; discontinue use if GI symptoms, jaundice, eosinophilia, or abnormal LFTs occur.
• Glaucoma: Use with caution in patients with glaucoma.
• Appropriate use: Not indicated for treatment of impotence by intracorporeal injection; persistent priapism may occur.
Blood pressure, heart rate
Pregnancy Risk Factor
Teratogenic effects have not been observed in animal reproduction studies.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience nausea, abdominal pain, fatigue, constipation, diarrhea, lack of appetite, loss of strength and energy, flushing, or sweating a lot. Have patient report immediately to prescriber signs of liver problems (dark urine, fatigue, lack of appetite, nausea, abdominal pain, light-colored stools, vomiting, or yellow skin), fast heartbeat, severe headache, dizziness, passing out, vision changes, or abnormal heartbeat (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about papaverine
- Side Effects
- Drug Images
- Drug Interactions
- Pricing & Coupons
- En Español
- Drug class: peripheral vasodilators
- FDA Alerts (2)
Other brands: Para-Time S. R.